Albumedix enters evaluation agreement with Novartis

By Maggie Lynch contact

- Last updated on GMT

(Image:Getty/scanrail)
(Image:Getty/scanrail)

Related tags: Evaluation, Drug delivery, Novartis

Novartis will use Albumedix’s Veltis drug delivery technology platform to develop several first-in-class therapeutics.

“Our Veltis technology platform offers multiple drug enhancement modalities for the development of more effective, safer and convenient therapeutics,” ​Jonas Skjodt Moller, COO of Albumedix, told us.

The platform, based on Albumedix’s engineered human albumin variant, has attracted interest by pharma and biotech companies looking to further enhance drug candidates, said Moller.

He continued, “Among other functional attributes this includes its validated capability to significantly prolong the duration of action of associated compounds.”

The agreement with Novartis covers the use of Albumedix technology across a range of molecules, targets, and mechanisms. Novartis could not comment further.

“We are very excited to be working with likeminded researchers at Novartis and see this as yet another step towards unlocking the full potential of albumin,”​ Moller said.

Related news

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars